Related Experiment Video
Updated: Aug 18, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners
Helen Rizos1, Sarah Woodruff, Richard F Kefford
1Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, Australia. helen_rizos@wmi.usyd.edu.au
Abstract:
The p14ARF tumour suppressor regulates a series of cell cycle regulatory proteins to promote cell cycle arrest in response to abnormal hyperproliferative growth stimuli. p14ARF alterations are common in human cancers and, when inherited, confer susceptibility to cutaneous melanoma. We now propose that the mechanism of p14ARF action may involve the covalent modification of its binding partners with the small ubiquitin-related protein SUMO-1. In particular, we demonstrate that p14ARF interacts with the SUMO E2 conjugating enzyme, Ubc9 and enhances the sumoylation of its binding partners, hdm2, E2F-1, HIF-1alpha, TBP-1 and p120E4F. Furthermore, p14ARF-induced sumoylation is abrogated by a subset of melanoma-associated p14ARF mutations. These results provide a mechanism for p14ARF action through a common modification of diverse binding partners.
Insights
The tumor suppressor p14ARF promotes cell cycle arrest by enhancing SUMO-1 modification of binding partners like hdm2 and E2F-1. Melanoma-associated p14ARF mutations disrupt this crucial sumoylation process.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- p14ARF is a tumor suppressor regulating cell cycle arrest in response to abnormal growth.
- Alterations in p14ARF are frequent in human cancers and linked to melanoma susceptibility.
- The precise mechanism of p14ARF action requires further elucidation.
Purpose of the Study:
- To investigate the role of SUMO-1 modification in p14ARF tumor suppressor function.
- To identify p14ARF binding partners that undergo SUMO-1 modification.
- To determine if cancer-associated p14ARF mutations affect this modification process.
Main Methods:
- Co-immunoprecipitation assays to detect protein interactions.
- Western blotting to assess SUMO-1 conjugation (sumoylation).
- Analysis of p14ARF interaction with Ubc9 and its effect on target protein sumoylation.
Main Results:
- p14ARF interacts with the SUMO E2 conjugating enzyme, Ubc9.
- p14ARF enhances the sumoylation of its binding partners: hdm2, E2F-1, HIF-1alpha, TBP-1, and p120E4F.
- Melanoma-associated p14ARF mutations impair p14ARF-induced sumoylation.
Conclusions:
- p14ARF utilizes SUMO-1 modification of diverse binding partners as a mechanism for tumor suppression.
- Disruption of p14ARF-mediated sumoylation by specific mutations may contribute to melanoma development.
- This study reveals a novel pathway for p14ARF action involving post-translational modification.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Anaphase Promoting Complex
Regulation of Nuclear Protein Sorting
Protein Modifications in the RER
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

